Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licartin and CIK for Preventing Relapse in Hepatocellular Carcinoma
NCT01758679Phase 4Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2012
- Primary completion
- Nov 2016
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 4 trial of licofelone, unmodified CIK in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
licofeloneunmodified CIK
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01758679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01758679.